Pathogen inactivation technology: Cleansing the blood supply

Harvey G. Klein

Research output: Contribution to journalArticle

Abstract

The calculated residual infectious risk of HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) from blood transfusion is extremely low. However, the risk of bacterial contamination remains and a variety of other agents including emerging viruses, protozoa and tick-borne agents threaten blood supplies and undermine public confidence in blood safety. Traditional methods of donor screening and testing have limited ability to further reduce disease transmission and cannot prevent an emerging infectious agent from entering the blood supply. Pathogen inactivation technologies have all but eliminated the infectious risks of plasma-derived protein fractions, but as yet no technique has proved sufficiently safe and effective for traditional blood components. Half-way technologies can reduce the risk of pathogen transmission from fresh frozen plasma and cryoprecipitate. Traditional methods of mechanical removal such as washing and filtration have limited success in reducing the risk of cell-associated agents, but methods aimed at sterilizing blood have either proved toxic to the cells or to the recipients of blood components. Several promising methods that target pathogen nucleic acid have recently entered clinical testing.

Original languageEnglish (US)
Pages (from-to)224-237
Number of pages14
JournalJournal of Internal Medicine
Volume257
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Technology
Blood Safety
Donor Selection
Infectious Disease Transmission
Poisons
Ticks
Hepatitis B virus
Blood Transfusion
Hepacivirus
Nucleic Acids
HIV
Viruses

Keywords

  • Blood safety
  • Pathogen reduction
  • Transfusion

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Pathogen inactivation technology : Cleansing the blood supply. / Klein, Harvey G.

In: Journal of Internal Medicine, Vol. 257, No. 3, 03.2005, p. 224-237.

Research output: Contribution to journalArticle

Klein, Harvey G. / Pathogen inactivation technology : Cleansing the blood supply. In: Journal of Internal Medicine. 2005 ; Vol. 257, No. 3. pp. 224-237.
@article{2e93e2c7f2cc434fa7e2d577fdb60593,
title = "Pathogen inactivation technology: Cleansing the blood supply",
abstract = "The calculated residual infectious risk of HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) from blood transfusion is extremely low. However, the risk of bacterial contamination remains and a variety of other agents including emerging viruses, protozoa and tick-borne agents threaten blood supplies and undermine public confidence in blood safety. Traditional methods of donor screening and testing have limited ability to further reduce disease transmission and cannot prevent an emerging infectious agent from entering the blood supply. Pathogen inactivation technologies have all but eliminated the infectious risks of plasma-derived protein fractions, but as yet no technique has proved sufficiently safe and effective for traditional blood components. Half-way technologies can reduce the risk of pathogen transmission from fresh frozen plasma and cryoprecipitate. Traditional methods of mechanical removal such as washing and filtration have limited success in reducing the risk of cell-associated agents, but methods aimed at sterilizing blood have either proved toxic to the cells or to the recipients of blood components. Several promising methods that target pathogen nucleic acid have recently entered clinical testing.",
keywords = "Blood safety, Pathogen reduction, Transfusion",
author = "Klein, {Harvey G.}",
year = "2005",
month = "3",
doi = "10.1111/j.1365-2796.2005.01451.x",
language = "English (US)",
volume = "257",
pages = "224--237",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Pathogen inactivation technology

T2 - Cleansing the blood supply

AU - Klein, Harvey G.

PY - 2005/3

Y1 - 2005/3

N2 - The calculated residual infectious risk of HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) from blood transfusion is extremely low. However, the risk of bacterial contamination remains and a variety of other agents including emerging viruses, protozoa and tick-borne agents threaten blood supplies and undermine public confidence in blood safety. Traditional methods of donor screening and testing have limited ability to further reduce disease transmission and cannot prevent an emerging infectious agent from entering the blood supply. Pathogen inactivation technologies have all but eliminated the infectious risks of plasma-derived protein fractions, but as yet no technique has proved sufficiently safe and effective for traditional blood components. Half-way technologies can reduce the risk of pathogen transmission from fresh frozen plasma and cryoprecipitate. Traditional methods of mechanical removal such as washing and filtration have limited success in reducing the risk of cell-associated agents, but methods aimed at sterilizing blood have either proved toxic to the cells or to the recipients of blood components. Several promising methods that target pathogen nucleic acid have recently entered clinical testing.

AB - The calculated residual infectious risk of HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) from blood transfusion is extremely low. However, the risk of bacterial contamination remains and a variety of other agents including emerging viruses, protozoa and tick-borne agents threaten blood supplies and undermine public confidence in blood safety. Traditional methods of donor screening and testing have limited ability to further reduce disease transmission and cannot prevent an emerging infectious agent from entering the blood supply. Pathogen inactivation technologies have all but eliminated the infectious risks of plasma-derived protein fractions, but as yet no technique has proved sufficiently safe and effective for traditional blood components. Half-way technologies can reduce the risk of pathogen transmission from fresh frozen plasma and cryoprecipitate. Traditional methods of mechanical removal such as washing and filtration have limited success in reducing the risk of cell-associated agents, but methods aimed at sterilizing blood have either proved toxic to the cells or to the recipients of blood components. Several promising methods that target pathogen nucleic acid have recently entered clinical testing.

KW - Blood safety

KW - Pathogen reduction

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=14844293483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844293483&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2796.2005.01451.x

DO - 10.1111/j.1365-2796.2005.01451.x

M3 - Article

C2 - 15715679

AN - SCOPUS:14844293483

VL - 257

SP - 224

EP - 237

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 3

ER -